Delayed Launch of PainReliefMeds.com Website

El Paso, TX -- (ReleaseWire) -- 01/05/2017 -- Premier Biomedical, Inc. (OTCQB:BIEI)

Dear Shareholders,

In my December CEO Letter, I indicated:

"Our current business plan is to offer our patent-pending, 96-hour pain relief patch, which we believe is the best in the industry, and a roll-on applicator, for sale on our website, painreliefmeds.com, beginning January 2, 2017. Additional pain relief products, including creams, sprays, gel pens, and capsules/pills (Pain-ExTM) will follow later in the year."

True to plan, we did secure the necessary tooling to support volume production of the pain patches; we completed the design and procurement of the packaging for the pain patch; kicked off volume production and have built up an inventory of patches that we project is sufficient to meet initial demand. We have the tooling and fixtures completed for production of the roll-on applicators as well.

Whether it is Murphy's Law at work or a case in point that prompted the poet Robert Burns to observe: "The best laid plans of mice and men often go awry." Premier Biomedical Pain Management Solutions' plans for our website to be up and running on January 2, 2017, didn't go off as scheduled. There are a lot of reasons for the delay, but no excuses. Since we worked through the holidays, we hadn't counted on key suppliers shutting down the week between Christmas and New Year's Day. Consequently, we are now faced with rescheduling issues of certain activities, as we have lost some of our windows of opportunity.

We are working diligently to complete the activities necessary to launch the website mid-January, 2017, but we are still relying on third party suppliers to make this happen, and there are a lot of things that can still go wrong. We are doing everything we can to mitigate those risks.

In addition, we are working to secure distribution agreements with a regional pharmacy chain as well as local pain management clinics to make our products available through their outlets. The experience gained through these relationships will serve us in the future as we look to eventually expand our retail distribution network nationwide.

When the website is up and ready to take orders for our pain patches and roll-ons, we will send an email to all of our subscribers, and to anyone who enters their email address on our temporary website landing page at www.painreliefmeds.com.

Thank you for your patience and understanding.

William A. Hartman
President and CEO
Premier Biomedical Inc.
724-633-7033
PR@premierbiomedical.com

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, focusing on two major areas -- 1) Biologics and Extracorporeal Treatments; and 2) Non-narcotic Pain Management Products. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending patents and provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI."

For more information please visit our website: http://www.premierbiomedical.com/.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedical-inc-update-ceo-letter-757273.htm

El Paso, TX -- (ReleaseWire) -- 12/06/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as potential novel therapies for pain management, announced today that a paper describing their groundbreaking metronomic cancer therapy work in conjunction with development of a patent pending CTLA4 anti-cancer antibody drug at the University of Texas El Paso (UTEP) has been accepted for publication by the prestigious British Journal of Cancer.

The paper, titled, "Impact of CTLA-4 Blockade In Conjunction With Metronomic Chemotherapy On Preclinical Breast Cancer Growth" was co-authored by a team of UTEP researchers led by Dr. Giulio Francia in consultation with Dr. Mitchell Felder, Chairman of Premier Biomedical's Scientific Advisory Board. The initial research on this topic was previously presented at the American Association for Cancer Research symposia in April, 2014 and again (updated) in April, 2016.

William A. Hartman, President and CEO of Premier Biomedical, stated, "We are pleased that this paper documenting our joint work with UTEP has been recognized as a significant contribution to the understanding and treatment of cancer by such a prestigious publication as the British Journal of Cancer. In addition to our joint work with UTEP on metronomic chemotherapy, our patent pending anti-cancer antibody drug not only outperformed standard chemo, but also outperformed the leading commercially available anti-cancer drug in initial animal tests. We are presently engaged in the antibody humanization process over the next 4-6 months and will commence further testing at that time."

For more information please contact:
William A. Hartman
President and CEO
Premier Biomedical Inc.
724-633-7033
w.hartman@premierbiomedical.com
http://www.premierbiomedical.com/

About The British Journal of Cancer
The British Journal of Cancer (BJC) is a multidisciplinary journal of cancer research. It is published twice monthly and is recognized as one of the most cited general cancer journals in the world, "providing a forum for prompt communication of original and innovative research findings that have relevance to understanding the etiology of cancer and to improving the treatment and survival of patients.

"BJC is owned by Cancer Research UK, the world's leading independent charity dedicated to cancer research. Cancer Research UK carries out scientific research to find news (sic) ways of preventing, diagnosing and treating cancer; ensuring findings are used to benefit the lives of cancer patients."[1]

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI."

For more information please visit our website: http://www.premierbiomedical.com/.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

[1] http://www.nature.com/bjc/about/aims_scope.html

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedicals-research-on-its-patent-pending-anti-cancer-treatment-with-metronomic-chemotherapy-recognized-for-publication-in-the-prestigious-british-journal-of-cancer-748900.htm

El Paso, TX -- (ReleaseWire) -- 07/18/2016 -- Premier Biomedical, Inc. (OTCQB: BIEI)

Greetings from the CEO and Staff at Premier Biomedical, Inc.

I would like to take this opportunity to update you, our shareholders, on developments at Premier Biomedical, Inc. through the second quarter of 2016:

COMPANY BALANCE SHEET & SHARE STRUCTURE
- In 2015, unfortunately we had as many as five different lenders at any one time providing financing to the company and selling our stock. This resulted in excessive selling pressure in the market and dropping our stock to the sub-penny level. Through management-driven financial restructuring, we have eliminated the five competing lenders and consolidated into a single capital source.
- In the second quarter, we worked with our primary funding source to establish long term financing on improved terms.
- We recognize that there has been a considerable amount of selling pressure recently, but have been working to moderate that pressure.
We understand that we can't continue to borrow money on a long term basis to fund ongoing research and development. In order to eliminate the resultant selling pressure associated with loans, we must develop a source of revenue or arrange a partnering relationship with a larger, well established pharmaceutical entity.

PARTNERSHIP STRATEGY/STATUS
- We have been working on development of partnerships with a company in Brazil and a group in Asia for nearly a year. This process has taken much more time and energy than initially anticipated, and still is yet to result in an acceptable agreement.
- We have modified our approach toward seeking relationships with multinational pharmaceutical firms as opposed to regional entities. Toward that end, we have established world-wide agents to represent our interests and have initiated contact with a number of potential partners.
- We have received emails and telephone calls from large pharmaceutical companies as a result of our press releases. As the development of our technology progresses, we believe that we will attract much more interest from suitable multinational partners, which could lead to a developmental business alliance.
- In the past, we had been working on a number of "specialty diseases" in an attempt to attract angel investors and pharmaceutical companies seeking specialty niches.
We have since concluded that we should focus our development efforts on two principal product groupings: 1) IMMUNOTHERAPY and 2) PAIN MANAGEMENT.
- Immunotherapy would include our recent excellent work on development of our patent-pending anti-cancer antibody (see press release 6-Jul-16), which recently outperformed a multi-billion dollar commercially available competitive drug in laboratory mouse testing. Future extensions of this technology to other diseases will also be included in this product grouping.
- Pain Management would include development of opioid-free pain killers addressing general, neuropathic, and localized pain symptoms. We are investigating numerous options, including diverse delivery methods, potentially with conventional, or unconventional ingredients, or both. When our product strategy is finalized, we will communicate our progress through press releases and corporate communications.

MANAGEMENT ADDITIONS
- The company announced in May, 2016, the appointment of Dr. James Frincke as Chief Technical Officer. Dr. Frincke has been working with Premier Biomedical for the past year as a member of our Scientific Advisory Board. (See our press release of 24-May-16 for more details). His expertise and experience in launching new pharmaceutical products and connections within the industry are expected to expedite our product market introductions and advance our partnering strategy.

ANTI-CANCER DRUG PROGRESS
- Two years ago, at the AACR Conference in San Diego, researchers presented our original anti-body which demonstrated capabilities of blocking breast cancer antigens at a rate of 36% in laboratory tests.
- In April, 2016, researchers from UTEP presented our most recent anti-breast cancer antibody test results at the American Association for Cancer Research (AACR) Conference held April 16-20, 2016 in New Orleans.
- Our 2016 patent-pending antibody was almost three times more effective than the 2014 version, demonstrating capabilities of blocking 98.8% of breast cancer antigens. We believe that this latest antibody is possibly more effective than other available treatments and are in the process of conducting confirmation tests.

STOCK SUPPORT ACTIONS
- We currently have support contracts with three investor relations/media/digital marketing firms:
o Uptick Newswire
o Vertical Communications
o Reinvent Business
- We have increased our focus on getting our message out through social media and encourage our stockholders and readers to follow us on these channels.
- We have tried other IR firms with limited success in the past, and will continue to search for the most cost effective firms in the future.

SUMMARY
- We are extremely pleased with the early mouse testing results which demonstrate superior performance of our patent-pending anti-cancer antibody versus commercially available antibodies from competitors. We believe that planned tests in the very near future will verify the superiority of our anti-cancer antibody and will attract the attention of large pharmaceutical firms to license our technology.
- We are optimistic that the strategic steps being taken in the pain management category could result in early commercialization of unique products and forms not requiring initial FDA approval. This first wave of products consisting of approved and natural ingredients could provide revenue to the corporation to fund further research and development of subsequent generations of products which require FDA testing.
I remain respectfully yours,

William A. Hartman

Contact

William A. Hartman
President & CEO
Premier Biomedical, Inc.
Contact Info: (724) 633-7033, PR@premierbiomedical.com

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedical-inc-ceo-letter-july-2016-updates-and-progress-on-partnership-initiatives-for-specialty-diseases-and-anti-cancer-drugs-research-707428.htm

El Paso, TX -- (ReleaseWire) -- 07/06/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) announced today the favorable results of initial multi-faceted mouse testing of their patent pending anti-cancer antibody versus commercially available competitive drugs.  The Premier Biomedical antibody, PBI-5D3H5, demonstrated superiority based on tumor volume and mouse survivability.

William Hartman, President and CEO of Premier Biomedical, Inc., said, "At the start of these initial tests, we were hoping for comparable performance of our antibody versus competitive products, but we were delighted about the demonstrated superior performance of our immunotherapy anti-cancer drug PBI-5D3H5 in these initial tests.  Testing also confirmed compatibility of our drug with human tissue.  Further testing of our drug is underway and is expected to be concluded within the next several months.  These test results reinforce the material presented at the American Association for Cancer Research Symposium earlier this year in New Orleans.  When the next series of tests are concluded, major announcements regarding specific results will be released."

Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB:BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans.  Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent.  Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI."  

For more information please visit our website: www.premierbiomedical.com/

Safe Harbor Notice
Certain statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.

Contact:
William A. Hartman
President and CEO
724-633-7033
PR@premierbiomedical.com.

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedical-anti-cancer-antibody-outperforms-leading-multi-billion-dollar-commercial-cancer-treatments-in-initial-head-to-head-testing-at-a-major-university-704287.htm

El Paso, TX -- (ReleaseWire) -- 05/31/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) reported today that it has consolidated its debt to one lender, a move that the company believes will minimize the toxic impact that having multiple lenders had on the market for its stock.

William A. Hartman, President and CEO of Premier Biomedical stated, "We no longer have multiple lenders competing in the market with each other to sell their loan conversion stock and have turned the corner on this harmful financing which has depressed our stock price, and now have only one lender working with us in a more constructive partnership. This should improve our financial health and long term prospects."

Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company's common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements". Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: Uptick Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedical-confirms-consolidation-of-debt-694294.htm

El Paso, TX -- (ReleaseWire) -- 05/24/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) announced the appointment of Dr. James Frincketo the position of Chief Technical Officer effective immediately.In this role, Dr. Frincke will report to the President and CEO of Premier, William A. Hartman. Dr. Frincke will retain his current position as a member of the company's Scientific Advisory board, which reports to Premier's co-founder and Chairman of the Scientific Advisory Board, Dr. Mitchell S. Felder, MD.

James Frincke, PhD, is a Research & Development Consultantat Red Spot Biosciences, LLC,currently providing pro bono consultation to physicians globally to discover treatments for diseases, such as Crohn's, Rheumatoid Arthritis, Alzheimer's, Parkinson's and Type 1 Diabetes. With over 30 years of experience in the biotechnology industry, Dr. Frincke has successfully managed major development programs for all phases of pharmaceutical development. Dr. Frincke received his PhD and BS degrees in Organic Chemistry from the University of California, Davis and has performed postdoctoral work in the area of drug metabolism.

Prior to Dr. Frincke's work as a consultant, he was VP of R&D Operations at Harbor Therapeutics, San Diego, CA, where he focused on treatments for age-related diseases. He is a world renowned pharmaceutical scientist and has raised hundreds of millions of dollars to fund new and groundbreaking small molecule compound (monoclonal antibody), biological, and cellular and gene therapies. Dr. Frincke is a prolific inventor with 24 US and 120 International patents to his credit. He has also published 75 peer reviewed journal articles and has submitted 32 new drug applications to the FDA.

William A. Hartman, President and CEO of Premier Biomedical stated, "Dr. Frincke's out standing level of drug development experience and business expertise will be put to full use to guide Premier through the complexities of the biomedical industry.Premier strongly believes that Dr. Frincke's larger role at Premier will be a tremendous help to guide and expedite our R&D programs currently underway at the University of Texas at El Paso (UTEP), and our many other technical and business related programs we are currently pursuing, and will be pursuing in the very near future."

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, initially targeting the treatment of cancer. The Company's common stock trades on the Over-The-Counter Bulletin Board under the ticker symbol "BIEI." www.premierbiomedicalinc.com

Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.

Contact:
Premier Biomedical
Website: http://www.premierbiomedical.com
Phone: 814-786-8849
Email: info@premierbiomedical.com

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedical-announces-the-appointment-of-dr-james-frincketo-chief-technical-officer-position-692275.htm

El Paso, TX -- (ReleaseWire) -- 04/25/2016 -- Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.

William A. Hartman, President and CEO of Premier Biomedical, stated, "This new drug has shown to be effective in blocking 98.8% of CTLA-4 breast cancer-causing antigens in laboratory tests, compared to 36% for the drug we presented in 2014. In our mouse testing, both of these antibodies demonstrated immunity to re-injections of breast cancer after treatment."

Hartman indicated that the company plans comparison tests of other available immunotherapy drugs to verify the belief that this new antibody may be the most effective anti-breast cancer drug in the world. "We have also developed antibodies against other cancer-causing antigens and plan animal tests to compare them to other available treatments in the near future," he said.

Contact William A. Hartman, President and CEO at 724-633-7033, PR@premierbiomedical.com.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB:BIEI) is a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol "BIEI." www.premierbiomedical.com/

Safe Harbor Notice
Statements made in this news release constitute forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Premier Biomedical makes no guarantee of future performance and actual results could differ materially. Premier Biomedical, Inc. undertakes no obligation to revise or update these.

Contact:
William A. Hartman, President and CEO
724-633-7033
PR@premierbiomedical.com

For more information on this press release visit: http://www.releasewire.com/press-releases/premier-biomedicalutep-demonstrate-new-anti-cancer-immunotherapy-drug-may-compete-against-best-of-big-pharma-drugs-684067.htm